编者按：在2026年SGO年会上，由韩国妇科肿瘤学会（KSGO）、日本妇科肿瘤学会（JSGO）与美国妇科肿瘤学会（SGO）举办的KSGO-JSGO-SGO联合专场，围绕卵巢癌展开深入研讨。本场会议由Jessica Ji Son医生（得克萨斯肿瘤中心-迪克·斯雷顿癌症中心）担任协调人，由日本JSGO的Yusuke Kobayashi医生（庆应义塾大学）、美国SGO的Melissa Pham医生（加州大学戴维斯分校健康中心）及韩国KSGO的Dong Hoon Suh医生（首尔大学盆唐医院）共同主持。

 

本次KSGO-JSGO-SGO联合专场分为三个环节，旨在推动三国妇科肿瘤医师在手术理念与前沿药物应用方面的经验互鉴。核心内容如下：

 

手术专场：纪念斯隆-凯特琳癌症中心的Dennis Chi医生基于TRUST试验最新数据，重新审视了初始肿瘤细胞减灭术（PDS）与新辅助化疗联合间歇性肿瘤细胞减灭术（NACT-IDS）的优效之争；里诺希望中心的Peter Lim医生探讨了机器人手术在晚期卵巢癌减灭术中的应用前景；亚洲大学医院的Suk-Joon Chang医生介绍了腹腔热灌注化疗（HIPEC）的应用进展。随后，本环节进入专家讨论。

 

全身治疗专场：埼玉医科大学国际医疗中心的Kosuke Shigematsu医生围绕PARP抑制剂、免疫检查点抑制剂（ICI）、贝伐珠单抗及抗体药物偶联物（ADC）等药物，探讨了晚期卵巢癌的个体化治疗选择与临床用药顺序；伊诺瓦·沙尔癌症研究所的Leslie Randall医生报告了ADC药物Elahere（mirvetuximab soravtansine）在铂耐药卵巢癌中的真实世界疗效与安全性数据。来自韩国和日本的青年医生代表分享了各自地区的药物可及性差异及临床实践经验。

多学科病例讨论：首尔大学医学院的Hyun-Ji Lim医生和日本国立癌症中心医院的Taro Yamanaka医生作为代表，分享了多学科视角的病例。

 

 

本报在会议现场特别采访了Melissa Pham医生、Dong Hoon Suh医生和Jessica Ji Son医生，就KSGO-JSGO-SGO联合专场的设计理念、学术焦点及跨国协作的临床启示进行了交流。

 

Melissa Pham：KSGO-JSGO-SGO联合专场完全是一项由所有学会通力协作的成果。考虑到本会议的主题围绕手术和全身化疗（尤其是随着抗体药物偶联物[ADC]及其他靶向治疗的进展），我们重点邀请了该领域当前的权威专家参与。我们很幸运地从SGO方面邀请到了Dennis Chi博士、Peter Lim博士以及Leslie Randall博士加入。

 

Dong Hoon Suh：我们还邀请了来自KSGO与JSGO的SukJoon Chang博士与Kosuke Shigematsu博士加入。肿瘤病例讨论环节我们安排了两位报告人，该环节旨在促进青年医师的成长。他们分别是来自日本的Taro Yamanaka，以及来自韩国的Hyun-Ji Lim。

 

Jessica Ji Son：每年我们KSGO-JSGO-SGO联合会议都会聚焦一个疾病领域。去年的主题是子宫内膜癌，我们对此进行了深入探讨。今年的主题则是卵巢癌。我们非常希望会议内容能够全面，并且每个学会都有代表参与。我们努力在各自的学会内部寻找该主题相关的专家。

 

Oncology Frontier:The KSGO-JSGO-SGO joint session represents a collaboration between KSGO，JSGO，and SGO.How were the speakers and topics selected for this session?What roles did each society play in the selection process?

 

Melissa Pham:It was very much a collaborative effort from all societies.Given that our topic centered around surgery and systemic chemotherapy(especially with the advancements of ADCs and other targeted treatments)，we focused on engaging current experts in the field.We were fortunate to have Dr.Dennis Chi and Dr.Peter Lim，and Dr.Leslie Randall join us from the SGO side.

 

Dong Hoon Suh：We also had Drs SukJoon Chang and Kosuke Shigematsu who joined us from KSGO and JSGO.We had two presenters for the Tumor Board，which is designed to promote early career physicians.They were Taro Yamanaka from Japan，and Hyun Ji Lim from Korea.

 

Jessica Ji Son:Every year，we have a disease site that the KSGO-JSGO-SGO joint session focuses on.Last year，the topic was endometrial cancer，and we had an in depth session on that.And this year it was on ovarian cancer.We very much wanted the session to be comprehensive and for there to be representation from each society.And we try to find the experts on that topic within each of our societies.

 

Melissa Pham：2026年KSGO-JSGO-SGO联合会议的第一个板块聚焦于手术。作为妇科肿瘤医生，我们同时承担着实施化疗的内科肿瘤学方面与外科手术方面的工作，并对我们专业中这两个方面都极为重视。在手术领域，关于NAC-IDS（新辅助化疗-间歇性肿瘤减灭术）是否优于PDS（初次肿瘤减灭术）的争论由来已久。近期发表的TRUST试验是2026年KSGO-JSGO-SGO联合专场第一板块的重点，我们很荣幸能请到Dennis Chi博士进行这一讲座。第二位讲者是Peter Lim博士，他聚焦于机器人手术，这恰恰是他的专长领域，其报告聚焦机器人手术能否作为卵巢癌减灭术工具的争议。

 

Jessica Ji Son：在2026年KSGO-JSGO-SGO联合会议的全身治疗板块中，我们围绕各国药物审批体系与机制的差异，以及患者获取这些疗法的可及性，展开了富有成果且饶有趣味的讨论。这对每一位参会者而言都是一次宝贵的学习机会。KSGO-JSGO-SGO联合会议的第三个板块为肿瘤病例讨论，回顾了几个有趣的病例。

 

Oncology Frontier:Could you please introduce the topics discussed in the KSGO-JSGO-SGO joint session and explain what clinical focuses each topic addresses?

 

Melissa Pham:The first part of KSGO-JSGO-SGO joint session focused on surgery.As gynecologic oncologists，we incorporate both the medical oncology aspect of administering chemotherapy and the surgical aspect，and we deeply value both sides of our profession.In surgery，there is an ongoing and longstanding debate regarding whether neoadjuvant chemotherapy is superior to primary debulking surgery(PDS vs.NAC-IDS).The recently published TRUST trial was the focus of the first session，and we were lucky to have Dr.Dennis Chi deliver that lecture.The second speaker was Dr.Peter Lim，who focused on robotic surgery，which is very much his area of expertise，and the session was designed to tackle the debate about whether robotic surgery is a tool for ovarian debulking surgery.

 

Jessica Ji Son:In the systemic therapy part of the KSGO-JSGO-SGO joint session，we had a very productive and interesting discussion concerning the differing drug approval landscapes and the mechanisms by which each country，and subsequently the patients，gain access to these therapies.It served as a valuable learning opportunity for every participant.The third part of our KSGO-JSGO-SGO joint session consisted of a tumor board reviewing several interesting cases.

 

Dong Hoon Suh：毫无疑问是ADC。如今抗体药物偶联物在妇科肿瘤领域无处不在。我们也把这个话题放进了KSGO-JSGO-SGO联合专场的第二板块（即全身治疗部分），并邀请了Kosuke Shigematsu医生分享他个人的临床经验。在韩国和日本，ADC的发展尚未达到最先进水平，市场份额还比较小，存在一些现实限制。在将一种新药引入日常临床实践之前，我们非常希望能听到经验丰富的专家分享真实世界的使用经验。

 

Oncology Frontier:At the 2026 SGO meeting，what research or topics do you think are most worthy of close attention?

 

Dong Hoon Suh:Undoubtedly，ADCs.Antibody-drug conjugates are now everywhere in gynecologic oncology.We included this topic in part 2 of our session as well(focus on systemic therapy).We invited Kosuke Shigematsu as the speaker to share his personal clinical experience.In Korea and Japan，we have not yet reached the same level of ADCs development—the market is still small，that sort of thing.Before introducing a new drug into daily clinical practice，we really want to listen to real-world experience from established experts.